Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Advaxis, Inc. is a biotechnology company, which engages in the discovery, development and commercialization of cancer immunotherapies. The company is headquartered in Princeton, New Jersey and currently employs 35 full-time employees. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins. These Lm-LLO strains integrate multiple functions into a single immunotherapy as they access and direct antigen presenting cells to stimulate anti-tumor T-cell immunity, stimulate and activate the immune system with the equivalent of multiple adjuvants, and simultaneously reduce tumor protection in the tumor microenvironment to enable the T-cells to eliminate tumors. Axalimogene filolisbac is its lead Lm-LLO immunotherapy product candidate for the treatment of Human Papilloma Virus-associated cancers. ADXS-PSA is its Lm-LLO immunotherapy product candidate that targets the Prostate Specific Antigen (PSA) associated with prostate cancer.
Website: advaxis.com



Growth: Bad revenue growth rate 0.0%, are preserved at an average historical level 0.0%. The revenue growth dynamics is unstable

Profitability: LTM EBITDA margin is negative, -1 050.0%. Gross margin is high, +63.6%. In the last quarter the company did not beat the estimated EPS. The company was ahead of estimated EPS in 75% of quarters (showing a gain of +$0.15 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield -991.2% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 6.7% higher than minimum and 98.8% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued -49.6x by EV / Sales multiple

Key Financials (Download financials)

Ticker: ADXS
Share price, USD:  (+4.6%)0.555
year average price 0.8550  


year start price 1.0500 2023-05-08

max close price 1.3800 2023-07-21

min close price 0.5200 2024-01-29

current price 0.5550 2024-05-06
Common stocks: 1 817 761

Dividend Yield:  0.0%
Last revenue growth (y/y):  -100.0%
Last growth of EBITDA (y/y):  ---
Historical revenue growth:  0.0%
Historical growth of EBITDA:  -12.8%
EV / Sales: -13.5x
Margin (EBITDA LTM / Revenue): -1 050.0%
Fundamental value created in LTM:
Market Cap ($m): 1
Net Debt ($m): -28
EV (Enterprise Value): -27
Price to Book: -0.0x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q3 2022 q2
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-10-31 2022-07-31
symbol ADXS ADXS ADXS ADXS ADXS ADXS
reportedCurrency USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M
fillingDate 2023-12-31 2023-11-20 2023-08-10 2023-05-23 2023-02-10 2022-09-13
acceptedDate 2023-12-30 19:00:00 2023-11-20 09:00:30 2023-08-10 16:01:53 2023-05-23 13:10:51 2023-02-09 20:11:38 2022-09-12 18:25:16
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q4
revenue 0 0 9000.000 4000.000 250 000 250 000
costOfRevenue 0 7M 9000.000 4000.000 0 91 000
grossProfit 0 -7M 0 0 250 000 159 000
grossProfitRatio 0 0 0 0 1.000 0.636
researchAndDevelopmentExpenses 5M 6M 6M 7M 2M 2M
generalAndAdministrativeExpenses 3M 1M 3M 5M 3M 3M
sellingAndMarketingExpenses 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 3M 1M 3M 5M 3M 3M
otherExpenses 0 0 0 0 0 5M
operatingExpenses 9M 7M 8M 12M 5M 10M
costAndExpenses 9M 7M 8M 12M 5M 5M
interestIncome 0 0 0 301 000 100 000 100 000
interestExpense 0 0 86 000 -301 000 4M 4M
depreciationAndAmortization 226 000 44 000 0 44 000 -34 000 -34 000
ebitda -9M -7M -8M -12M -5M -5M
ebitdaratio 0 0 -942.889 -2956.250 -19.548 -19.548
operatingIncome -9M -7M -8M -12M -5M -5M
operatingIncomeRatio 0 0 -942.889 -2967.250 -19.412 -19.412
totalOtherIncomeExpensesNet -16M 7M 8M 301 000 262 000 262 000
incomeBeforeTax -25M -7M -9M -12M -5M -5M
incomeBeforeTaxRatio 0 0 -952.444 -2892.000 -18.364 -18.364
incomeTaxExpense 103 000 65 000 127 000 -4M 373 000 373 000
netIncome -25M -7M -9M -7M -5M -5M
netIncomeRatio 0 0 -966.556 -1840.250 -19.856 -19.856
eps 0 -1.530 -1.820 -1.670 -2.730 -2.730
epsdiluted 0 -1.530 -1.820 -1.670 -2.730 -2.730
weightedAverageShsOut 0 5M 5M 4M 2M 2M
weightedAverageShsOutDil 0 5M 5M 4M 2M 2M
link Link Link Link Link Link
finalLink Link Link Link Link Link

Balance Sheet Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q3 2022 q2
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-10-31 2022-07-31
symbol ADXS ADXS ADXS ADXS ADXS ADXS
reportedCurrency USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M
fillingDate 2023-12-31 2023-11-20 2023-08-10 2023-05-23 2023-02-10 2022-09-13
acceptedDate 2023-12-30 19:00:00 2023-11-20 09:00:30 2023-08-10 16:01:53 2023-05-23 13:10:51 2023-02-09 20:11:38 2022-09-12 18:25:16
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q4
cashAndCashEquivalents 5M 2M 7M 17M 25M 25M
shortTermInvestments 0 0 0 0 0 0
cashAndShortTermInvestments 5M 2M 7M 17M 25M 25M
netReceivables 0 0 0 4000.000 0 129 000
inventory 0 0 0 108 000 0 -129 000
otherCurrentAssets 172 000 2M 2M 1M 551 000 551 000
totalCurrentAssets 8M 5M 10M 18M 26M 26M
propertyPlantEquipmentNet 642 000 2M 2M 2M 50 000 50 000
goodwill 5M 0 0 0 0 0
intangibleAssets 4M 107 000 115 000 130 000 110 000 110 000
goodwillAndIntangibleAssets 8M 107 000 115 000 130 000 110 000 110 000
longTermInvestments 0 0 0 0 0 0
taxAssets 0 0 0 0 0 0
otherNonCurrentAssets 11 000 201 000 208 000 212 000 11 000 11 000
totalNonCurrentAssets 9M 2M 3M 3M 171 000 171 000
otherAssets 0 0 0 0 0 0
totalAssets 17M 7M 12M 21M 26M 26M
accountPayables 6M 5M 4M 4M 1M 1M
shortTermDebt 166 000 480 000 542 000 253 000 12 000 12 000
taxPayables 0 0 0 0 0 0
deferredRevenue 6M -5M -4M 0 0 0
otherCurrentLiabilities 12M 8M 8M 5M 1M 1M
totalCurrentLiabilities 25M 9M 8M 10M 2M 2M
longTermDebt 8M 3M 1 000 000 1M 0 396 000
deferredRevenueNonCurrent 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0
otherNonCurrentLiabilities 8M 2M 2M 77 000 34 000 -362 000
totalNonCurrentLiabilities 16M 5M 3M 1M 34 000 34 000
otherLiabilities 0 0 0 0 -34 000 -34 000
capitalLeaseObligations 175 000 1M 2M 2M 12 000 12 000
totalLiabilities 41M 13M 11M 11M 2M 2M
preferredStock 0 0 0 0 0 0
commonStock 12 000 5000.000 5000.000 5000.000 2000.000 2000.000
retainedEarnings -197M -173M -165M -157M -443M -443M
accumulatedOtherComprehensiveIncomeLoss 0 0 0 0 0 0
othertotalStockholdersEquity 173M 166M 166M 166M 467M 467M
totalStockholdersEquity -24M -6M 1M 10M 24M 24M
totalEquity -24M -6M 1M 10M 24M 24M
totalLiabilitiesAndStockholdersEquity 17M 7M 12M 21M 26M 26M
minorityInterest 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 17M 7M 12M 21M 26M 26M
totalInvestments 0 0 0 0 0 0
totalDebt 8M 3M 2M 2M 12 000 12 000
netDebt 3M 1M -6M -15M -25M -25M
link Link Link Link Link Link
finalLink Link Link Link Link Link

Cash Flow Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q3 2022 q2
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-10-31 2022-07-31
symbol ADXS ADXS ADXS ADXS ADXS ADXS
reportedCurrency USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M
fillingDate 2023-12-31 2023-11-20 2023-08-10 2023-05-23 2023-02-10 2022-09-13
acceptedDate 2023-12-30 19:00:00 2023-11-20 09:00:30 2023-08-10 16:01:53 2023-05-23 13:10:51 2023-02-09 20:11:38 2022-09-12 18:25:16
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q4
netIncome -25M -7M -9M -7M -5M -5M
depreciationAndAmortization 226 000 44 000 0 44 000 38 000 38 000
deferredIncomeTax 6M -10M 0 0 0 0
stockBasedCompensation 0 89 000 0 1M 23 000 23 000
changeInWorkingCapital 1M 174 000 0 -520 000 2M 2M
accountsReceivables 0 0 0 230 000 0 133 000
inventory 0 0 0 0 0 -133 000
accountsPayables -2M 637 000 0 -892 000 395 000 395 000
otherWorkingCapital 3M -463 000 0 142 000 1M 1M
otherNonCashItems 10M 10M 9M -90 000 -128 000 -128 000
netCashProvidedByOperatingActivities -7M -7M 0 -7M -3M -3M
investmentsInPropertyPlantAndEquipment 0 0 0 0 201 000 201 000
acquisitionsNet 0 0 0 0 0 0
purchasesOfInvestments 0 0 0 0 0 0
salesMaturitiesOfInvestments 0 0 0 0 0 0
otherInvestingActivites 0 0 0 0 -166 000 -166 000
netCashUsedForInvestingActivites 6M -5M 0 0 35 000 35 000
debtRepayment -4M 0 0 0 0 0
commonStockIssued 0 0 0 21M 0 468 000
commonStockRepurchased 0 0 0 0 18 000 18 000
dividendsPaid 0 0 0 0 0 0
otherFinancingActivites 0 0 0 0 -18 000 -504 000
netCashUsedProvidedByFinancingActivities 4M 2M 0 21M -18 000 -18 000
effectOfForexChangesOnCash 52 000 15 000 0 -36 000 18 000 18 000
netChangeInCash 3M -5M -10M 14M -3M -3M
cashAtEndOfPeriod 5M 2M 7M 17M 25M 25M
cashAtBeginningOfPeriod 2M 7M 17M 3M 28M 28M
operatingCashFlow -7M -7M 0 -7M -3M -3M
capitalExpenditure 0 0 0 0 201 000 201 000
freeCashFlow -7M -7M 0 -7M -3M -3M
link Link Link Link Link Link
finalLink Link Link Link Link Link

Earning call transcript

Press-releases

Show financial reports only

2024-03-26 12:00 ET
Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome
2024-02-20 13:00 ET
Ayala Pharmaceuticals Announces Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors
2024-02-06 13:00 ET
Immunome to Acquire AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals
2024-02-06 13:00 ET
Immunome To Acquire AL102, A Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals
2023-11-06 13:00 ET
Ayala Pharmaceuticals Announces AL102 Receives Orphan Drug Designation for Desmoid Tumors
2023-10-23 11:00 ET
Ayala Pharmaceuticals Presents Updated AL102 Results from Phase 2 Clinical Trial in Desmoid Tumors at ESMO Congress 2023
2023-10-19 12:00 ET
Ayala Pharmaceuticals Announces Closing of Merger with Biosight
2023-08-10 20:30 ET
Ayala Pharmaceuticals Announces Second Quarter 2023 Financial Results and Provides Corporate Update
2023-08-01 12:00 ET
Ayala Pharmaceuticals Announces Abstracts on AL102 and AL101 Accepted for Presentation at ESMO Congress 2023
2023-07-27 12:10 ET
Ayala Pharmaceuticals and Biosight Enter into Definitive Merger Agreement
2023-07-05 12:00 ET
Ayala Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA Regarding AL102 for the Treatment of Desmoid Tumors
2023-06-05 12:00 ET
Updated RINGSIDE Phase 2 Results Featured in Poster Discussion Session at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
2023-05-25 21:05 ET
Ayala Pharmaceuticals Announces Updated RINGSIDE Phase 2 Results at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
2023-05-23 17:20 ET
Ayala Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Corporate Update
2023-04-27 12:00 ET
Ayala Pharmaceuticals Announces RINGSIDE Results to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
2023-03-03 13:00 ET
Ayala Pharmaceuticals Announces Continuation of RINGSIDE Phase 2/3 Study in Desmoid Tumors Following Recommendation of Independent Data Monitoring Committee
2023-02-10 12:00 ET
Ayala Pharmaceuticals Reports Financial Results For the Fiscal Year Ended October 31, 2022
2023-01-12 13:04 ET
Advaxis Updates on the Phase 1 Clinical Trial of ADXS-504 for the Treatment of Early Prostate Cancer
2022-09-12 22:40 ET
Advaxis Reports Third Quarter Ended July 31, 2022 Financial Results and Provides a Business Update
2022-06-03 20:05 ET
Advaxis, Inc. Announces 1-for-80 Reverse Stock Split
2022-05-26 21:00 ET
Advaxis to Present Updated Clinical and Immunogenicity Data from Ongoing Phase 1/2 Trial of ADXS-503 in Metastatic Non-Small-Cell Lung Cancer (NSCLC) and Study Design of ADXS-504 Trial in Early Prostate Cancer at the American Society of Clinical Oncol...
2022-04-27 14:00 ET
Advaxis to Present at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting
2022-04-08 12:00 ET
Advaxis Announces Publication of ADXS-PSA Data in The Oncologist
2022-03-17 13:00 ET
Advaxis Reports First Quarter Ended January 31, 2022 Financial Results and Provides a Business Update
2022-02-14 21:35 ET
Advaxis Reports Fiscal Year 2021 Financial Results and Provides a Business Update
2022-01-28 13:00 ET
Advaxis Prices Offering of $5,000,000 of Convertible Redeemable Preferred Stock Through a Private Placement
2022-01-11 13:00 ET
Advaxis Presents Updated Clinical Data from Ongoing Phase 1/2 Trial of ADXS-503 in NSCLC and Upcoming Milestones
2021-12-23 12:00 ET
OTC Markets Group Welcomes Advaxis, Inc. to OTCQX
2021-12-22 21:05 ET
Advaxis Announces Acceptance for Trading on the OTCQX
2021-12-17 13:00 ET
Advaxis to Continue to Explore Additional Options to Maximize Stockholder Value
2021-12-09 13:00 ET
Advaxis Issues Letter to Stockholders Regarding Recent Special Meeting Results
2021-11-24 13:00 ET
Advaxis Issues Letter and Second Video Message to Stockholders Regarding Upcoming Special Meeting
2021-11-22 13:00 ET
Nasdaq Grants Advaxis, Inc. an Extension to December 20, 2021, to Complete Merger Transaction with Biosight, Ltd. and Satisfy Initial Listing Requirements
2021-11-19 13:00 ET
Advaxis, Inc. Issues Letter to Stockholders
2021-11-18 13:00 ET
Leading Independent Proxy Advisory Firm Glass Lewis Joins ISS in Recommending Advaxis Stockholders Vote “FOR” Proposed Merger with Biosight
2021-11-11 13:00 ET
Biosight Encourages Advaxis Stockholders to Vote “FOR” Proposed Merger
2021-11-04 12:00 ET
Advaxis Issues Letter and Video Message to Stockholders Regarding Upcoming Special Meeting
2021-11-03 12:00 ET
Leading Independent Proxy Advisory Firm ISS Recommends Advaxis Stockholders Vote “FOR” the Merger with Biosight
2021-09-10 12:30 ET
Advaxis Reports 3rd Quarter Ended July 31, 2021 Financial Results and Provides a Business Update
2021-08-11 12:00 ET
Nasdaq Grants Advaxis, Inc. an Extension to November 22, 2021, to Regain Compliance with the $1.00 Minimum Bid Price Rule and Complete Merger Transaction with Biosight, Ltd.
2021-07-15 12:00 ET
Advaxis Announces Initiation of Phase 1 Clinical Trial of ADXS-504 for the Treatment of Early Prostate Cancer
2021-07-14 20:01 ET
Advaxis to Present at the Non-Small Cell Lung Cancer Drug Development Summit
2021-07-06 10:00 ET
Advaxis and Biosight Announce Entry into Definitive Merger Agreement
2021-06-14 20:05 ET
Advaxis Reports Second Quarter Ended April 30, 2021 Financial Results and Provides a Business Update
2021-05-19 21:01 ET
Advaxis Presents Updated Clinical Data from Ongoing Phase 1/2 Trial of ADXS-503 in NSCLC at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting
2021-04-28 20:30 ET
Advaxis to Present at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting
2021-04-26 15:07 ET
UPDATE - Advaxis Announces Achievement of Second Milestone Under ADXS-HER2 Licensing Agreement with OS Therapies
2021-04-26 12:00 ET
Advaxis Announces Receipt of Second Milestone Payment Under ADXS-HER2 Licensing Agreement with OS Therapies
2021-04-12 12:30 ET
Advaxis, Inc. Announces $20 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
2021-04-10 12:31 ET
Advaxis Presents Translational Biomarker Data from Ongoing ADXS-503 Phase 1/2 Lung Cancer Trial at the American Associated for Cancer Research (AACR) 2021 Annual Meeting
2021-04-05 12:00 ET
Advaxis Announces Agreement with Columbia University Irving Medical Center to Fund Phase 1 Study of ADXS-504 for the Treatment of Early Prostate Cancer
2021-03-23 15:33 ET
Advaxis to Present Corporate Overview at the Benzinga Biotech Small Cap Conference
2021-03-16 13:00 ET
Advaxis Reports First Quarter Ended January 31, 2021 Financial Results and Provides a Business Update
2021-03-12 13:00 ET
Advaxis to Present at the American Association for Cancer Research (AACR) 2021 Annual Meeting
2021-01-25 12:00 ET
Advaxis Reports Fiscal Year 2020 Financial Results and Provides a Business Update
2021-01-19 13:00 ET
Advaxis Announces Receipt of Funding Milestone Payment Under ADXS-HER2 Licensing Agreement with OS Therapies
2020-12-22 18:42 ET
Advaxis Announces Listing Transfer to Nasdaq Capital Market and Additional 180-day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule
2020-11-27 17:07 ET
Advaxis, Inc. Announces Closing of $9.2 Million Public Offering
2020-11-24 13:30 ET
Advaxis, Inc. Announces Pricing of $8 Million Public Offering
2020-11-23 21:05 ET
Advaxis, Inc. Announces Proposed Public Offering of Common Stock and Warrants to Purchase Common Stock
2020-11-09 13:01 ET
Advaxis Presents Updated Data from Ongoing ADXS-503 Phase 1/2 Lung Cancer Trial at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting
2020-10-26 12:00 ET
Advaxis’ ADXS-503 (HOT Lung) Demonstrates Pronounced and Sustained Tumor Control in Ongoing Phase 1/2 Lung Cancer Trial
2020-10-15 12:00 ET
Advaxis to Present Data from Ongoing ADXS-503 Phase 1/2 Clinical Trial at SITC 2020
2020-09-29 12:30 ET
Advaxis, Inc. Adopts Limited Duration Stockholder Rights Plan
2020-09-24 12:00 ET
Advaxis Announces FDA Clearance of New IND for ADXS-504 for Treatment of Prostate Cancer
2020-09-10 12:00 ET
Advaxis Reports Third Quarter Ended July 31, 2020 Financial Results and Provides a Business Update
2020-09-04 20:30 ET
Advaxis Announces Resignation of Chief Financial Officer
2020-08-27 12:00 ET
Advaxis to Present Corporate Overview at the LD Micro 500 Virtual Conference
2020-08-03 12:00 ET
Advaxis Announces Common Stock Purchase Agreement for up to $20 Million with Lincoln Park Capital
2020-06-23 12:00 ET
Advaxis to be Featured in “Grand Rounds: a Webinar in Biotech and Specialty Pharma,” Hosted by Alliance Global Partners
2020-06-11 12:00 ET
Advaxis Reports Second Quarter Ended April 30, 2020 Financial Results and Provides a Business Update
2020-06-01 12:00 ET
Advaxis to Host Second Quarter Financial Results and Business Update Conference Call on Thursday, June 11, 2020
2020-05-14 12:00 ET
Advaxis Announces Updated Positive Clinical and Biomarker Data from Ongoing Phase 1/2 ADXS-503 Trial in NSCLC
2020-03-13 13:00 ET
Advaxis Reports First Quarter Ended January 31, 2020 Financial Results and Provides a Pipeline Update
2020-03-03 21:01 ET
Advaxis to Present at the 2020 LD Micro Virtual Conference
2020-02-27 14:00 ET
Advaxis Announces Updated Positive Clinical Data in Ongoing Phase 1/2 ADXS-503 Trial in NSCLC at I/O 360° Conference
2020-02-20 13:00 ET
Advaxis Announces Positive Clinical Data in Ongoing Phase 1/2 ADXS-503 Trial in NSCLC at the IASLC 2020 Targeted Therapies of Lung Cancer Meeting
2020-02-13 13:00 ET
Advaxis Announces Updated Survival Data in Phase 1/2 ADXS-PSA Trial at the ASCO Genitourinary Cancers Symposium
2020-02-11 13:00 ET
Advaxis and Personalis Announce Research Agreement to Deploy ImmunoID NeXT Platform in the ADXS-503 Clinical Program
2020-01-30 14:23 ET
Data on Advaxis’ Clinical Programs to be Presented at Upcoming Medical Meetings
2020-01-21 13:30 ET
Advaxis, Inc. Announces Pricing of $10.5 Million Registered Direct Offering
2020-01-07 13:00 ET
Advaxis Announces FDA Clearance of IND for ADXS-504 for Treatment of Prostate Cancer
2019-12-20 13:00 ET
Advaxis Reports Fiscal Year 2019 Financial Results and Provides a Business Update
2019-12-04 13:00 ET
Advaxis to Present at 12th Annual LD Micro Main Event Investor Conference
2019-12-03 13:00 ET
Advaxis Announces Submission of IND Application for ADXS-HOT Drug Candidate for Prostate Cancer
2019-10-24 13:00 ET
Advaxis Announces Business and Pipeline Update
2019-10-10 12:00 ET
Advaxis and UCLA Enter Collaboration for Glioblastoma Immunotherapy Discovery Research
2019-10-07 12:00 ET
Advaxis Announces Updated Prolonged Survival Data in Phase 1/2 ADXS-PSA Trial
2019-09-09 12:00 ET
Advaxis Reports Fiscal Third Quarter 2019 Financial Results and Provides Pipeline Update
2019-04-01 13:31 ET
Thinking about buying stock in Aurora Cannabis Inc., Advaxis Inc., Caesars Entertainment Corp., Estre Ambiental Inc., or New Concept Energy Inc.?
2019-03-12 12:00 ET
Advaxis Reports First Quarter Fiscal 2019 Financial Results and Provides Clinical Pipeline Update
2019-03-11 12:00 ET
Advaxis Announces Presentations of ADXS-NEO and ADXS-PSA Data at Upcoming American Association for Cancer Research Annual Meeting
2019-02-14 13:30 ET
Advaxis Announces Enrollment of the First Patient in its Phase 1/2 Trial for ADXS-HOT in the Treatment of Non-Small Cell Lung Cancer

SEC forms

Show financial reports only

SEC form 10
2024-04-16 16:11 ET
Advaxis reported for 2023 q4
SEC form 10
2024-04-16 00:00 ET
Advaxis reported for 2023 q4
SEC form 10
2023-11-20 09:00 ET
Advaxis reported for 2023 q3
SEC form 10
2023-11-20 00:00 ET
Advaxis reported for 2023 q3
SEC form 10
2023-08-10 16:01 ET
Advaxis reported for 2023 q2
SEC form 10
2023-08-10 00:00 ET
Advaxis reported for 2023 q2
SEC form 6
2023-08-01 09:00 ET
Advaxis published news for 2023 q2
SEC form 6
2023-06-23 12:35 ET
Advaxis published news for 2023 q1
SEC form 10
2023-05-23 13:10 ET
Advaxis reported for 2023 q1
SEC form 10
2023-05-23 00:00 ET
Advaxis reported for 2023 q1
SEC form 6
2023-05-15 16:05 ET
Advaxis published news for 2023 q1
SEC form 6
2023-04-07 17:20 ET
Advaxis published news for 2023 q1
SEC form 6
2023-04-06 17:24 ET
Advaxis published news for 2023 q1
SEC form 10
2023-02-10 00:00 ET
Advaxis reported for 2022 q3
SEC form 10
2022-09-13 00:00 ET
Advaxis reported for 2022 q2
SEC form 10
2022-06-08 00:00 ET
Advaxis reported for 2022 q1
SEC form 10
2022-03-17 00:00 ET
Advaxis published news for 2021 q4
SEC form 10
2022-02-14 00:00 ET
Advaxis published news for 2021 q3
SEC form 8
2021-09-10 00:00 ET
Advaxis published news for 2021 q2
SEC form 10
2021-09-10 00:00 ET
Advaxis published news for 2021 q2
SEC form 10
2021-06-14 00:00 ET
Advaxis published news for 2021 q1